
Cimzia clinical response, disease activity tied to productivity gains
Long-term use of Cimzia (certolizumab pegol) is associated with a higher clinical response to treatment and lower disease activity in people with axial spondyloarthritis (axSpA). This translated to increased productivity for patients, both at work and in household activities. “This highlights the importance of targeting these thresholds to limit…